Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proteomic profiling in advanced pancreatic adenocarcinoma treated with PDXG or PEXG
2009-013029-41Phase 4Completed
- Sponsor
- Fondazione Centro San Raffaele
- Start
- Jun 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cisplatin, docetaxel, capecitabine, gemcitabine and epirubicin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Fondazione Centro San Raffaele. Primary endpoints: Predictive value of serum proteomic profiling and Correlation of proteomic profiling with clinical outcome. Started Jun 2009; status: completed.
02
Drugs
cisplatindocetaxelcapecitabinegemcitabineepirubicin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2009-013029-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013029-41.